NR1I2 and prostate cancer: Pregnane X receptor (PXR), a transcriptional activator, can sense and remove foreign substances by regulating the expression of drug-metabolizing enzymes and drug transporters.457 In prostate cancer, PXR leads to dasatinib resistance but increases erlotinib, dabrafenib, and afatinib sensitivity.